Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cariporide Aventis.

B Chin1, G Y Lip

  • 1University of Birmingham, University Department of Medicine, Dudley Road, Birmingham, B18 7QH, UK.

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diving responses elicited by nasopharyngeal irrigation mimic seizure-associated central apneic episodes in a rat model.

Neurobiology of disease·2018
Same author

State of play and future direction with NOACs: An expert consensus.

Vascular pharmacology·2018
Same author

Glycative and oxidative stress are associated with altered thrombus composition in diabetic patients with ST-elevation myocardial infarction.

International journal of cardiology·2017
Same author

Reply to Jolobe

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Clinical Stroke prevention in atrial fibrillation.

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Short runs of atrial arrhythmia and stroke risk: a European-wide online survey among stroke physicians and cardiologists.

The journal of the Royal College of Physicians of Edinburgh·2016

Cariporide, a sodium/hydrogen ion exchange inhibitor, is being developed to treat myocardial infarction (MI) and related ischemic damage. Despite initial setbacks and revised timelines, ongoing trials explore its potential in acute MI and coronary artery bypass grafting (CABG).

Area of Science:

  • Cardiovascular Pharmacology
  • Ischemic Heart Disease Therapeutics
  • Ion Transport Inhibition

Background:

  • Cariporide is a novel sodium/hydrogen ion exchange inhibitor developed by Aventis Pharma.
  • It targets myocardial cells, aiming to prevent damage during ischemic events like myocardial infarction (MI).
  • The drug's mechanism involves inhibiting ion exchange to prevent anaerobic metabolism consequences.

Purpose of the Study:

  • To evaluate cariporide as a potential treatment for myocardial infarction (MI).
  • To assess cariporide's efficacy in preventing ischemic damage during angioplasty and reperfusion.
  • To explore cariporide's role in managing conditions associated with myocardial ischemia and anaerobic metabolism.

Main Methods:

  • Cariporide inhibits the sodium/hydrogen ion exchange in myocardial cells.

Related Experiment Videos

  • This action prevents lactic acid buildup and subsequent calcium overload during anaerobic metabolism.
  • Clinical trials, including Phase II/III studies, are evaluating cariporide's safety and efficacy.

    • Main Results:

    • Phase III GUARDIAN trial for MI did not achieve statistical significance, leading to trial suspension.
    • Ongoing Phase II trials are investigating cariporide in acute MI patients.
    • A Phase III trial for coronary artery bypass grafting (CABG) patients is planned, with earlier trials showing promise.

    Conclusions:

    • Cariporide's development for MI has faced challenges, including trial suspensions.
    • Further clinical investigation is ongoing, particularly for acute MI and in the context of CABG procedures.
    • Market launch projections have been revised, with ongoing evaluations determining its therapeutic potential and commercial viability.